Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials

22. April 2019 aktualisiert von: Case Comprehensive Cancer Center
The goal of this research study is to find out if providing patients who are enrolled in phase 1 clinical trials with structured supportive care will enable them to continue in the Phase 1 trial longer and improve their quality of life by reducing or treating side effects and by providing emotional and social support to the patient and family. The structured supportive or palliative care intervention will be provided by a team of trained specialists which include doctors, nurses, social workers and spiritual care providers. The supportive care team will provide treatment to address symptoms, such as pain or anxiety, caused by the cancer itself or from the treatment. The team can make referrals to other specialists. Such as psychologists or nutritionist, if needed, and can help arrange for services to address home care needs.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Primary Objective(s): To assess symptoms, adverse events, duration on study, reason for study discontinuation, and quality of life among patients participating in phase I clinical trials who receive structured palliative care, and those who receive standard supportive care. Duration on study will serve as the primary objective for sample size determination.

Secondary Objective(s):

1. To describe the quantity (e.g. hours), type, and cost of palliative care personnel services used by patients and caregivers receiving structured palliative care.

Exploratory:

  1. To compare adverse event profiles, duration on study, and quality of life between patients who receive structured palliative care and those receiving standard supportive care.
  2. To compare caregiver burden and quality of life between the study arms.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

132

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44106
        • Case Comprehensive Cancer Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Patient Inclusion Criteria:

  • Patients must be enrolled in a Phase 1 clinical trial and be within 2 weeks of starting the experimental therapy or intervention.
  • Patients are eligible to enroll on this study with or without the enrollment of their caregiver.

Patient Exclusion Criteria:

  • Patients diagnosed with a hematologic malignancy.

Caregiver Inclusion Criteria:

  • Any caregiver is considered eligible for this study; The caregiver is the person identified by the patient as the one who provides the most regular physical and/or emotional support.
  • Caregivers must be willing to complete surveys at baseline and on monthly basis.

Caregiver Exclusion Criteria:

  • Caregivers who are solely professional, paid caregivers

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Standard Supportive Care
Verhalten: Standard supportive care
Supportive care for the patient and caregiver will be provided by the treating oncologist.
Experimental: Structured Supportive Care
Verhalten: Structured palliative care
Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Average total MSAS score
Zeitfenster: Up to 6 months
Assessment of patient burden
Up to 6 months
Average total FACT-G score
Zeitfenster: Up to 6 months
Measure patient quality of life
Up to 6 months
Reason for study discontinuation (Patient reported outcome)
Zeitfenster: Up to 6 months
Measure of central tendency for why patients discontinued the phase I study. Patient reported outcomes for reason for study discontinuation will be qualitatively assessed
Up to 6 months
Duration on Study
Zeitfenster: Up to 6 months
Measure of central tendency of the duration patients were on the phase I study. Duration on study will serve as the primary objective for sample size determination
Up to 6 months
Adverse events
Zeitfenster: Up to 6 months
Measure of central tendency of adverse events. AE will be described and further categorized as modifiable (primary symptom experience) and non-modifiable (laboratory abnormalities). The influence of adverse events on study outcomes particularly duration on study and reason for study discontinuation will be assessed. An exploratory weighted adverse event score will be calculated using the equation: adverse event score = ∑ (NAE * GAE) where N denotes the adverse event number, G denotes grade, AE denotes adverse event. These scores will be compared between study arms
Up to 6 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mean number of hours of palliative care services
Zeitfenster: Up to 6 months
Mean number of hours utilized by patients and caregivers who received structured palliative care. This analysis will be descriptive, reporting measures of central tendency
Up to 6 months
Type of palliative care services
Zeitfenster: Up to 6 months
Measure of central tendency for the type of palliative care services utilized by patients and caregivers who received structured palliative care. This analysis will be descriptive, reporting measures of central tendency
Up to 6 months

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Frequency of adverse events of patients receiving structured and usual supportive care
Zeitfenster: Up to 6 months
Up to 6 months
Average days on study
Zeitfenster: Up to 6 months
Up to 6 months
Change in FACT-G score
Zeitfenster: From baseline to last contact, up to 6 months
Change in patient symptom burden when compared to baseline between patients who received structured palliative care and those who received standard supportive care
From baseline to last contact, up to 6 months
Change in MSAS score
Zeitfenster: From baseline to last contact, up to 6 months
Change in quality of life when compared to baseline between patients who received structured palliative care and those who received standard supportive care
From baseline to last contact, up to 6 months
Change in CRA score
Zeitfenster: From baseline to last contact, up to 6 months
Change in caregiver burden when compared to baseline between those who received structured palliative care and those who received standard supportive care
From baseline to last contact, up to 6 months
Change in QOLLTI-F score
Zeitfenster: From baseline to last contact, up to 6 months
Change in caregiver quality of life as assessed through change in QOLLTI-F score when compared to baseline between those who received structured palliative care and those who received standard supportive care
From baseline to last contact, up to 6 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Case Comprehensive Cancer Center

Ermittler

  • Hauptermittler: Michelle Treasure, MD, Metrohealth Medical Center and Case Comprehensive Cancer Center

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

25. Oktober 2015

Primärer Abschluss (Tatsächlich)

10. Januar 2019

Studienabschluss (Tatsächlich)

10. Januar 2019

Studienanmeldedaten

Zuerst eingereicht

4. September 2015

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

4. September 2015

Zuerst gepostet (Schätzen)

7. September 2015

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. April 2019

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. April 2019

Zuletzt verifiziert

1. April 2019

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • CASE5Y15

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Standard supportive care

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Lithuania

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren